

# Jakob J Malin

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3826837/jakob-j-malin-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23  
papers

3,909  
citations

10  
h-index

30  
g-index

30  
ext. papers

5,539  
ext. citations

12.1  
avg, IF

5.19  
L-index

#	Paper	IF	Citations
23	Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.. <i>Lancet Microbe, The</i> , <b>2022</b> , 3, e203-e214	22.2	2
22	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.. <i>Lancet, The</i> , <b>2022</b> ,	40	6
21	SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. <i>The Cochrane Library</i> , <b>2022</b> ,	5.2	1
20	Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.. <i>Lancet Infectious Diseases, The</i> , <b>2021</b> ,	25.5	16
19	SARS-CoV-2 neutralizing antibody treatment in COVID-19 patients with immunodeficiency due to B-cell non-Hodgkin lymphoma.. <i>Blood Advances</i> , <b>2021</b> ,	7.8	2
18	A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. <i>EMBO Molecular Medicine</i> , <b>2021</b> , 13, e13105	12	32
17	Recommendations on the In-Hospital Treatment of Patients With COVID-19. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , <b>2021</b> ,	2.5	5
16	Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19. <i>EMBO Molecular Medicine</i> , <b>2021</b> , 13, e14150	12	27
15	Plasma interferon-Inducible protein 10 (IP-10) levels correlate with disease severity and paradoxical reactions in extrapulmonary tuberculosis. <i>Infection</i> , <b>2021</b> , 49, 437-445	5.8	1
14	Predictors of serofast state after treatment for early syphilis in HIV-infected patients. <i>HIV Medicine</i> , <b>2021</b> , 22, 165-171	2.7	0
13	Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 825-827	5.1	19
12	DGI recommendations for COVID-19 pharmacotherapy. <i>Infection</i> , <b>2021</b> , 49, 369-370	5.8	1
11	Key summary of German national treatment guidance for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021). <i>Infection</i> , <b>2021</b> , 1	5.8	6
10	Outbreak of Pseudomonas aeruginosa infections after CT-guided spinal injections. <i>Journal of Hospital Infection</i> , <b>2021</b> , 116, 1-9	6.9	0
9	Clinical Practice Guideline: Recommendations on Inpatient Treatment of Patients with COVID-19. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , <b>2021</b> , 118,	2.5	18
8	Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020. <i>Eurosurveillance</i> , <b>2020</b> , 25,	19.8	8
7	Remdesivir for the Treatment of Covid-19 - Final Report. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1813-1826	59.2	3562

6	Remdesivir against COVID-19 and Other Viral Diseases. <i>Clinical Microbiology Reviews</i> , <b>2020</b> , 34,	34	97
5	Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection. <i>HIV Medicine</i> , <b>2019</b> , 20, 230-236	2.7	9
4	Extremely Low Hit Rate in a Diverse Chemical Drug Screen Targeting Mycobacterium abscessus. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	7
3	Therapeutic compounds targeting Lipid II for antibacterial purposes. <i>Infection and Drug Resistance</i> , <b>2019</b> , 12, 2613-2625	4.2	17
2	Effect of a small molecule Lipid II binder on bacterial cell wall stress. <i>Infection and Drug Resistance</i> , <b>2017</b> , 10, 69-73	4.2	1
1	Turning defense into offense: defensin mimetics as novel antibiotics targeting lipid II. <i>PLoS Pathogens</i> , <b>2013</b> , 9, e1003732	7.6	41